The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer

The effects of enzalutamide monotherapy on prostate tumor downsizing and multiparametric MRI are currently unknown. Here we present the first case in literature of a patient with high-grade prostate cancer who underwent 3 months of neoadjuvant enzalutamide, for which the effects on mpMRI and histolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Van der Roest, Rosanne CV., van Houdt, Petra J., Heijmink, Stijn WTPJ., de Jong, Jeroen, Bergman, André M., Zwart, Wilbert, van der Heide, Uulke A., van der Poel, Henk G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909636/
https://www.ncbi.nlm.nih.gov/pubmed/27335799
http://dx.doi.org/10.1016/j.eucr.2016.04.010
Descripción
Sumario:The effects of enzalutamide monotherapy on prostate tumor downsizing and multiparametric MRI are currently unknown. Here we present the first case in literature of a patient with high-grade prostate cancer who underwent 3 months of neoadjuvant enzalutamide, for which the effects on mpMRI and histology were determined. Tumor size reduction and downstaging were noted. Neoadjuvant enzalutamide resulted in an increase in ADC value on the DWI-MRI sequences. Histological changes were also observed.

Ejemplares similares